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ABSTRACT
Background and Purpose. In rat middle cerebral arteries, endothelium-dependent
hyperpolarization (EDH) is mediated by activation of calcium-activated potassium
(KCa) channels specifically KCa2.3 and KCa3.1. Lipoxygenase (LOX) products func-
tion as endothelium-derived hyperpolarizing factors (EDHFs) in rabbit arteries
by stimulating KCa2.3. We investigated if LOX products contribute to EDH in rat
cerebral arteries.
Methods. Arachidonic acid (AA) metabolites produced in middle cerebral arteries
were measured using HPLC and LC/MS. Vascular tension and membrane poten-
tial responses to SLIGRL were simultaneously recorded using wire myography and
intracellular microelectrodes.
Results. SLIGRL, an agonist at PAR2 receptors, caused EDH that was inhibited by a
combination of KCa2.3 and KCa3.1 blockade. Non-selective LOX-inhibition reduced
EDH, whereas inhibition of 12-LOX had no effect. Soluble epoxide hydrolase (sEH)
inhibition enhanced the KCa2.3 component of EDH. Following NO synthase (NOS)
inhibition, the KCa2.3 component of EDH was absent. Using HPLC, middle cerebral
arteries metabolized 14C-AA to 15- and 12-LOX products under control conditions.
With NOS inhibition, there was little change in LOX metabolites, but increased
F-type isoprostanes. 8-iso-PGF2α inhibited the KCa2.3 component of EDH.
Conclusions. LOX metabolites mediate EDH in rat middle cerebral arteries. Inhi-
bition of sEH increases the KCa2.3 component of EDH. Following NOS inhibition,
loss of KCa2.3 function is independent of changes in LOX production or sEH in-
hibition but due to increased isoprostane production and subsequent stimulation
of TP receptors. These findings have important implications in diseases associated
with loss of NO signaling such as stroke; where inhibition of sEH and/or isoprostane
formation may of benefit.
Subjects Biochemistry, Biophysics, Anatomy and Physiology, Pharmacology
Keywords Endothelium, Lipoxygensase, Isoprostane, Calcium-activated potassium channels,
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INTRODUCTION
Endothelium dependent hyperpolarization (EDH) is an extremely important vasodilator
pathway, particularly in resistance size arteries, and has a major role in regulation of blood
pressure; as such the EDH pathway has become intensively studied and targeting this
pathway could result in new classes of antihypertensive and possibly antithrombotic
therapies (Kohler, Kaistha & Wulff, 2010; Kro¨tz et al., 2010). The exact nature of EDH is
still unresolved but involves several different mechanisms that include release of diffusible
factors (endothelium derived hyperpolarizing factors; EDHFs) (Mombouli et al., 1996), di-
rect myo-endothelial cell coupling via gap junctions (Sandow et al., 2002) and increases in
extracellular potassium concentration in the myo-endothelial space (Edwards et al., 1998)
that all result in smooth muscle cell hyperpolarization. The relative contribution of each
mechanism varies between vascular beds and species (Edwards, Feletou & Weston, 2010).
Despite heterogeneity in the pathway, a feature of EDH responses in most vascular
beds is the critical role of endothelial cell calcium-activated potassium channels (KCa).
Blockade of both KCa2.3 (SKCa) and KCa3.1 (IKCa) is required to fully inhibit EDH
responses (Edwards, Feletou & Weston, 2010). In contrast, in the rat middle cerebral artery
(MCA), inhibition of KCa3.1 channels alone is sufficient to fully block the EDH response
obtained but only if NO synthase (NOS) is inhibited (Marrelli, Eckmann & Hunte, 2003;
McNeish, Dora & Garland, 2005). KCa2.3 channels are expressed in the endothelium of
MCA (Cipolla et al., 2009; McNeish et al., 2006) and contribute to EDH of smooth muscle
cells (SMC) in vessels that are able to synthesize NO (McNeish et al., 2006). KCa2.3 channel
function is lost following inhibition of NOS (McNeish et al., 2006), but can be restored
upon inhibition of the thromboxane prostanoid (TP) receptor and associated subsequent
Rho kinase mediated signalling (McNeish & Garland, 2007; McNeish et al., 2012).
In the MCA, EDH responses are also attenuated by inhibition of PLA2 suggesting a
role for a metabolite of arachidonic acid (AA) (Marrelli et al., 2007; McNeish & Garland,
2007; You, Marrelli & Bryan, 2002). A similar inhibition of EDH by PLA2 inhibitors has
also been reported in peripheral arterial beds including mesenteric and coronary arteries
(Hecker et al., 1994; Hutcheson et al., 1999). AA metabolism is complex and produces
a large number of biologically active metabolites that affect vascular tone (Campbell
& Falck, 2007). AA metabolites produced by the cyclooxygenase (COX), epoxygenase
and lipoxygenase (LOX) pathways modulate KCa. The 12- and 15-LOX pathways of
AA metabolism have been implicated in the EDH response (Campbell et al., 1996;
Chawengsub, Gauthier & Campbell, 2009; Nithipatikom et al., 2001a). Metabolites of
15-LOX, 15-hydroxy-11,12-epoxyeicosatrienoic acid (HEETA) and its soluble epoxide
hydrolase (sEH) metabolite, 11,12,15-trihydroxyeicosatrienoic acid (THETA), have been
characterized as EDHFs in rabbit arteries where they stimulate KCa2.3 channels (Campbell
& Gauthier, 2013). Rats express a LOX that has both 12- and 15-LOX activity (Watanabe
et al., 1993). Therefore, it is possible that LOX metabolites acting on KCa2.3 could also
contribute EDH in the rat MCA.
NO can potentially interact with the synthesis of many AA metabolites by binding to the
heme group of these enzymes (Minamiyama et al., 1997). Therefore, TP receptor-mediated
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inhibition of KCa2.3 following inhibition of NOS (McNeish & Garland, 2007) may be due
to altered synthesis of AA metabolites such as thromboxane A2 (TxA2) or isoprostanes that
stimulate the TP receptor. Alternately following inhibition of NOS, there may be a change
in production of AA metabolites that normally stimulate KCa2.3.
As changes in AA metabolism following inhibition of NOS could potentially affect
KCa2.3 function in the MCA, these studies were designed to identify the AA metabolites
and determine if these metabolites contribute to EDH in the MCA. Second, we investigated
the effect of NOS inhibition on AA metabolism and if any change in metabolite production
contributes to the loss of KCa2.3 function.
MATERIALS AND METHODS
Male Wistar or Sprague Dawley rats (200–300 g, circa 8–10 weeks old) were humanely
killed in accordance with local ethics committee guidelines. The brain was removed and
immediately placed in ice-cold Krebs’ solution. Segments of the middle cerebral artery
(∼2 mm long) were dissected and stored in ice-cold Krebs’ for use (usually within 30 min
but if first vessel failed to meet the exclusion criteria detailed below a second vessel would
be mounted this was never>4 h), with similar size vessels used in all experimental groups.
Simultaneous measurement of membrane potential and tension
Smooth muscle membrane potential was measured simultaneously with vasomotor
responses using isometric recording technique. Segments of MCA (internal diameter
∼150 µm) were mounted in a Mulvany–Halpern myograph (model 400A; Danish
Myotechnology) in Krebs’ solution containing (mM): NaCl, 118.0, NaCO3, 24; KCl,
3.6; MgSO4·7H2O, 1.2; glucose, 11.0; CaCl2, 2.5; gassed with 21% O2, 5% CO2, balance
N2 and maintained at 37 ◦C. After equilibration for 20 min, vessels were tensioned to
1–1.5 mN (approximates wall tension at 60 mmHg). Smooth muscle tension was recorded
with an isometric pressure transducer and Powerlab software (ADI, Australia). Vessel
viability was assessed by adding exogenous K+ (15–55 mM, total K+ concentration);
only vessels developing tension of ≥3 mN were used. Endothelial cell viability was
assessed by the ability of an agonist of protease activated receptor 2, SLIGRL (serine,
leucine, isoleucine, glycine, arginine, leucine; 20 µM) to relax spontaneous tone and to
hyperpolarize the smooth muscle cell membrane by >15 mV. SLIGRL was chosen to
stimulate the endothelium as more commonly used agonists such as ACh are unable to
evoke an EDH response in the MCA and purinergic agonists that can stimulate EDH
responses evoke constriction via smooth muscle cell action.
All endothelium-dependent responses to SLIGRL (20 µM) were obtained in resting
vessels with no vasoconstrictor stimulus other than spontaneous tone unless stated
otherwise. EDH of smooth muscle cells was assessed in the presence of the KCa channel
blockers, apamin (KCa2.3, 50 nM), TRAM-34 (KCa3.1, 1 µM) and iberiotoxin (KCa1.1,
100 nM). The effect of KCa blockers on EDH responses was also assessed after addition of
three structurally distinct non-selective inhibitors of LOX (ebselen, nordihydroguaiaretic
acid (NGDA), both 1 µM, and PD146176, 5 µM), soluble epoxide hydrolase (sEH)
inhibitor tAUCB (10 µM) and isoprostane isoPGF2α (1 µM). Isolated EDH responses
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were obtained in the presence of the NO synthase inhibitor L-NAME (100 µM). In these
experiments, the effect of the KCa channel blockers was assessed on EDH responses
induced by SLIGRL (20 µM) in the presence of tAUCB or tempol (100 µM). Papaverine
(150 µM) was added at the end of each experiment to assess overall tone and all relaxations
are expressed as a percentage of this maximal relaxation. All drugs were allowed to
equilibrate for at least 20 min before EDH responses were stimulated. In most experiments,
smooth muscle membrane potential (Em) and tension were measured simultaneously
as previously described, using glass microelectrodes (filled with 2 M KCl; tip resistance,
80–120 MΩ) to measure Em (Garland & McPherson, 1992). In experiments where vessels
were able to synthesise NO we only reported EDH of the smooth muscle cell layer as NO
was able to evoke relaxation even if EDH was blocked.
Measurement of metabolites of 14C-labelled AA
Rat cerebral arteries were dissected, cleaned, cut into 2–3 mm rings, and incubated at
37 ◦C with indomethacin (10 µM) and vehicle or indomethacin and L-NAME (100 µM)
in 2 ml of N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES) buffer (mM):
10 HEPES, 150 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 6 glucose, pH 7.4. After 10 min, [14C]-AA
(0.5 µCi, 10−7 M) was added, incubation was continued for 5 min, and then A23187
(10 µM) was added. After 15 min, the reaction was stopped with ethanol (15% final
concentration). The incubation buffer was removed and extracted using Bond Elute
octadecylsilyl columns as previously described (Pfister et al., 1998). The extracts of the
media were analyzed by reverse phase high-pressure liquid chromatography (HPLC) using
a Nucleosil C-18 (5µ, 4.6× 250 mm) column (Pfister et al., 1998). Solvent system 1 was
used to resolve lipoxygenase and epoxygenase metabolites and consisted of a 40 min linear
gradient (flow rate= 1 ml/min) from 50% solvent B (acetonitrile with 0.1% glacial acetic
acid) in solvent A (deionized water) to 100% solvent B. Column effluent was collected in
0.2 ml fractions, and the radioactivity was determined. In a separate series of incubations,
arterial rings were incubated with vehicle or L-NAME (100 µM) as described above.
Following extraction of the media, prostaglandins and isoprostanes were resolved using
a Nucleosil C-18 column using solvent system 2. This solvent system consisted of an 40 min
isocratic elution with 31% solvent B (acetonitrile) in solvent A (water containing 0.025 M
phosphoric acid) followed by a 20 min linear gradient to 100% B and a 10 min elution with
100% B. The column eluate was collected in 0.5 ml fractions and radioactivity determined.
Total radioactivity from a sample was normalized to tissue weight.
The extracts were analyzed using liquid chromatography–mass spectrometry (LC/MS)
with an Agilent Model 1100SL mass selective detector and electrospray ionization
(Nithipatikom et al., 2001b; Nithipatikom et al., 2003). Metabolites were resolved using
a Kromasil C-18 (5 µm, 2× 250 mm) column. Solvent system 3 consisted of a 10 min
linear gradient from 15% solvent B (acetonitrile) in solvent A (water containing 0.005%
glacial acetic acid) to 60% solvent B in A, a 10 min linear gradient to 80% solvent B in
A followed by 5 min gradient to 100% B. The flow rate was 0.2 ml/min. The drying gas
flow was 12 l/min. The nebulizer pressure was 35 psig, vaporizer temperature was 325 ◦C
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and desolvation temperature 350 ◦C. The capillary voltage was 3 kV and fragmentor
voltage was 120 V. Detection was in the negative ion mode. For isoprostanes, the eluate was
monitored at m/z 351 (M-H) for PGE2-type isoprostanes and m/z 353 for PGF2-type
isoprostanes. Comparisons were made with the elution times of known isoprostane
standards.
Data analysis and statistical procedures
Results are expressed as the mean± s.e.m. of n animals. Tension values are given in mN
(always per 2 mm segment) and Em as mV. Vasodilatation is expressed as percentage
reduction of the total vascular tone (spontaneous tone plus vasoconstrictor response),
quantified by relaxation with papaverine (150 µM). Graphs were drawn and comparisons
made using one-way ANOVA with Tukeys’ post-test or Students’ t-test, as appropriate
(Prism, GraphPad). P ≤ 0.05 was considered significant.
Drugs, chemicals, reagents and other materials
Exogenous K+ was added as an isotonic physiological salt solution in which all the
NaCl was replaced with an equivalent amount of KCl. Concentrations of K+ used
are expressed as final bath concentration. Ebselen (2-Phenyl-1,2-benzisoselenazol-
3(2H)-one), L-NAME (NG-nitro-L-arginine methyl ester), Nordihydroguaiaretic
acid (NDGA), papaverine HCl, PD 146176 (6,11-Dihydro[1]benzothiopyrano[4,3-
b]indole), tempol (4-Hydroxy-2,2,6,6-tetramethylpiperidine 1-oxyl), TRAM-34
(1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole) and U46619 (9,11-Dideoxy-
11α,9α-epoxymethanoprostaglandin F2α) were all obtained from Sigma (Poole, U.K.).
Apamin and iberotoxin, from Latoxan (Valence, France). SLIGRL-NH2 (serine, leucine,
isoleucine, glycine, arginine, leucine) from Auspep (Parkville, Australia). 8-iso PGF2α
from Cayman-Europe (Tallinn, Estonia). tAUCB (trans-4-[4-(3-Adamantan-1-yl-ureido)-
cyclohexyloxy]-benzoic acid) was a generous gift from Professor Bruce D. Hammock
(University of California, Davis). All stock solutions (100 mM) were prepared in
dimethylsulfoxide (DMSO) except L-NAME, apamin, iberiotoxin, papaverine and SLIGRL
that were dissolved in 0.9% NaCl and tempol which was dissolved in ultrapure water.
Vehicle controls were performed when necessary.
RESULTS
Effect of LOX and sEH inhibition on EDH
In our previous studies, control arteries that had not been treated with a NOS inhibitor
demonstrate endothelium-dependent hyperpolarization (EDH) that has components
from KCa2.3, KCa3.1 and KCa1.1 channels (McNeish & Garland, 2007; McNeish et al.,
2006). A similar pattern was seen in this study. Control EDH was significantly inhibited
only by the combination of the KCa3.1 inhibitor TRAM-34 and the KCa2.3 inhibitor
apamin; TRAM-34 alone had no significant inhibition alone (Fig. 1B); apamin alone
was not assessed in this study but our previous studies demonstrate alone it does not
have a significant effect on EDH under these conditions (McNeish & Garland, 2007;
McNeish et al., 2006). The residual EDH was blocked by the inhibitor of KCa1.1 (BKCa),
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Figure 1 Effect of lipoxygenase inhibition on endothelium-dependent hyperpolarization (EDH) evoked by SLIGRL (20 µM) in rat middle
cerebral arteries that are able to synthesize NO. (A) An original, representative trace showing control EDH (upper panel) and the effect of the
non-selective lipoxygenase inhibitor NDGA (1 µM) on EDH (lower panel). Also shown are bar graphs showing (B) control EDH and the effect of
lipoxygenase inhibitors NDGA (C) and ebselen (1 µM) (D) as well as the effect subsequent inhibition of KCa3.1 (TRAM-34) KCa2.1 (apamin) and
KCa1.1 (iberiotoxin) on EDH. Control EDH was only inhibited following inhibition of KCa2.3 and KCa3.1 in the combined presence of apamin
and TRAM-34, respectively. NDGA and ebselen significantly inhibited EDH, the residual hyperpolarization was inhibited by TRAM-34 alone,
subsequent addition of apamin and IbTx had no significant additional effect. ∗P < 0.05 indicates a significant difference from control.
iberiotoxin. SLIGRL (20 µM) evoked EDH (−30.0± 5.5 mV, n= 4) that was significantly
reduced by the LOX inhibitor nordihydroguaiaretic (NDGA, 1 µM;−10.7± 2.3 mV; n= 4,
P < 0.05; Figs. 1A and 1C). This hyperpolarization was further reduced by TRAM-34
(−4.3± 2.4 mV, n = 5) but not by subsequent additions of apamin and iberiotoxin
(Fig. 1B). NDGA also abolished spontaneous tone (1.9± 0.6 vs 0.2± 0.2 mN, pre- and
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post-NDGA, respectively, n = 4, P < 0.05). This relaxation was not associated with
significant hyperpolarization (Em − 44.6± 3.0 vs 51.9± 4.3 mV, pre- and post-NDGA,
respectively, n = 4). A structurally distinct blocker of LOX, ebselen (10 µM), had similar
effects. Ebselen significantly inhibited EDH (−28.8± 2.2 mV vs−15.6± 2.9 mV, pre- and
post-ebselen, respectively; P < 0.05, n = 6; Fig. 1C). Hyperpolarization that was resistant
to ebselen was not significantly reduced by TRAM-34 (Fig. 1C) or further addition of
apamin but the subsequent addition of iberiotoxin reduced hyperpolarization further
(Fig. 1D). Ebselen also reduced spontaneous tone (0.6± 0.0 mN vs 0.3± 0.1 mN, pre-
and post-ebselen, respectively, n = 6,P < 0.05) that was not associated with significant
hyperpolarization (Em− 44.3± 1.0 vs−49.0± 3.3 mV, pre- and post-ebselen, respectively,
n = 6). A third LOX inhibitor, PD146176 (5 µM), also reduced EDH (−27.5± 3.1
and −9.8± 2.6 mV pre- and post-PD146176 respectively, n = 5,P < 0.05). PD146176
also reduced spontaneous tone (1.5± 0.3 and 0.2± 0.1 mN pre- and post-PD146176
respectively, n = 5,P < 0.05) that was not associated with significant hyperpolarization
(Em − 52.1± 3.9 vs −58.7± 4.5 mV, pre- and post-PD146176, respectively, n = 5).
The similar effect of these three structurally different LOX inhibitors to inhibit EDH
and abolish the KCa2.3 component of this response indicates a role for LOX-derived AA
metabolites in EDH.
Previous studies indicate that the LOX-derived HEETA is metabolized by sEH to
THETA (Chawengsub et al., 2008). Inhibition of sEH reduced HEETA metabolism and
enhanced EDH to AA suggesting an important role for HEETA in mediating EDH.
The inhibitor of sEH, tAUCB (10 µM) did not significantly effect EDH to SLIGRL
in control vessels (−33.5± 5.4 vs 30.8± 6.0 mV pre- and post-tAUCB, respectively
n = 5). Following inhibition of KCa3.1 and KCa1.1 with the combination TRAM-34 and
iberiotoxin, the residual hyperpolarization to SLIGRL (−17.8± 2.8 mV, n= 5) is mediated
solely by KCa2.3. Under these conditions, the KCa2.3-mediated hyperpolarization was
significantly augmented by tAUCB (−29.2± 3.6, P < 0.05,n = 6, Figs. 2A and 2B). This
augmented response is specific for KCa2.3 since addition of apamin significantly inhibited
EDH (−7.0± 2.0 mV, P < 0.05, Figs. 2A and 2B). Therefore, an epoxide-containing
LOX metabolite of AA contributes to the KCa2.3 component of EDH and is normally
metabolized by sEH.
Effect of tAUCB and superoxide scavenging on EDH responses in
the presence of L-NAME
In the presence of the NOS inhibitor L-NAME, inhibition of KCa3.1 alone abolishes EDH
(McNeish, Dora & Garland, 2005; McNeish et al., 2006). The absence of a KCa2.3 compo-
nent reflects activation of TP receptors (McNeish & Garland, 2007). Similarly, in this study,
the isolated EDH-mediated response obtained in the presence of L-NAME (hyperpolariza-
tion of 23.1± 4.6 mV and relaxation of 74.3± 5.3%, n= 8) was significantly attenuated by
TRAM-34 alone (hyperpolarization of−6.5± 1.5 mV and relaxation of 25.0± 4.2%,n=
5; Fig. 2C). Application of tAUCB to TRAM-34-treated arteries failed to recover the EDH
response (hyperpolarization of −4.2± 2.4 mV and relaxation of 23.7± 2.7%,n = 5;
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Figure 2 The effect of the sEH inhibitor tAUCB on the KCa2.3 component of endothelium-dependent hyperpolarization (EDH) in rat middle
cerebral arteries able to synthesize NO. (A) Original traces of KCa2.3-mediated hyperpolarization obtained in the presence of: the KCa3.1
inhibitor TRAM-34 and KCa1.1 inhibitor iberiotoxin (upper trace), the subsequent addition of tAUCB (middle trace) and the combination of
tAUCB and the KCa2.3 inhibitor, apamin. (B) Bar graph showing control EDH, KCa2.3 dependent EDH in the presence and absence of tAUCB
and further addition of apamin. The KCa2.3-dependent hyperpolarization was significantly smaller than control EDH and was potentiated by
tAUCB this hyperpolarization was completely abolished by apamin indicating that it was mediated solely by KCa2.3. (C) Bar graph showing
the SLIGRL-induced EDH mediated hyperpolarization (left panel) and relaxation (right panel) in the presence of the NOS inhibitor L-NAME.
TRAM-34 significantly attenuated EDH responses and the subsequent addition of t-AUCB had no further effect. Under these conditions, there is
no contribution from KCa2.3 channels and tAUCB failed to restore the function of this channel. (D) Bar graphs showing the SLIGRL-induced EDH
mediated hyperpolarization (left panel) and relaxation (right panel) in the presence tempol and the NOS inhibitor L-NAME. Tempol restored a
KCa2.3 component to the EDH response and also revealed a KCa1.1 component (n= 5). ∗P < 0.05 indicates a significant difference from control,
ΨP < 0.05 indicates a significant difference from TRAM-34+ IbTx (KCa2.3 hyperpolarization).
Fig. 2C). In the combined presence of L-NAME and tempol, a cell permeable superoxide
scavenger, isolated EDH responses to SLIGRL were significantly inhibited only by the com-
bination of TRAM-34 and apamin. Further inhibition of KCa1.1 with iberiotoxin abolished
the residual EDH response (Fig. 2D). Thus, tempol restored the KCa2.3 component to the
EDH whereas inhibition of sEH failed to restore this component of EDH.
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Figure 3 Effect of the NOS inhibitor L-NAME on arachidonic acid metabolism by rat cerebral arter-
ies. Arteries were incubated with 14C-AA and indomethacin in the absence (A) and presence of L-NAME
(B). Metabolites were extracted and separated by reverse-phase HPLC, solvent system 1. Migration times
of known standards are shown on each chromatogram. CPM, counts per minute; THETA, trihydroxye-
icosatrienoic acid; HEETA, hydroxyepoxyeicosatrienoic acid; HETE, hydroxyeicosatetraenoic acid; AA,
arachidonic acid.
AA metabolism of the rat middle cerebral artery
Since LOX metabolites mediate a component of EDH, we investigated the metabolism of
14C-AA by cerebral arteries. In arteries treated with the COX inhibitor, indomethacin,
to facilitate the identification of LOX metabolites, the products of AA metabolism
were resolved by reverse phase HPLC using solvent system 1. 14C-Labelled metabolites
co-migrated with the LOX products THETAs, HEETAs, 15-HETE and 12-HETE (Fig. 3A).
There were virtually no AA metabolites eluting with the EETs indicating that it is unlikely
that the middle cerebral artery produces cytochrome P450 epoxygenase products. In the
presence of the NOS inhibitor L-NAME, there was a significant change in the profile of
AA metabolism. Metabolites co-migrating with 12-HETE and 15-HETE were markedly
increased whereas the metabolites co-migrating with the THETAs and HEETAs increased
slightly (Fig. 3B). Arteries were also incubated in the presence and absence of L-NAME and
the metabolites resolved by reverse phase HPLC using solvent system 2 that resolves COX
metabolites and isoprostanes. Indomethacin was not present in these incubations. Metabo-
lites comigrating with 6-keto PGF1α , 8-iso-PGF2 and 12-HETE were detected (Fig. 4). A
14C-metabolite comigrating with TxB2 was not observed. Following L-NAME treatment,
there was also a marked increase in polar metabolites eluting in fractions 5–10 and possibly
8-iso-PGF2, eluting in fractions 33–34 (Fig. 4). Isoprostane synthesis was confirmed by
LC/MS analysis. Extracts were purified by reverse phase HPLC using solvent system 3 and
the eluate monitored by selected ion monitoring of m/z 351 for PGE2-type isoprostanes
and m/z 353 for PGF2-type isoprostanes (Fig. 5). The production of 8-iso-PGE2 was
similar in control and L-NAME-treated arteries (380 and 335 ng/ml, respectively;
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Figure 4 Effect of L-NAME on arachidonic acid metabolism by rat cerebral arteries. Arteries were
incubated with 14C-labeled arachidonic acid in the absence (control, solid line) and presence of L-NAME
(100 mM) (dotted line). Metabolites were extracted and separated by reverse-phase HPLC, solvent system
2. Migration times of known standards are shown on each chromatogram. CPM, counts per minute; PG,
prostaglandin; TX, thromboxane; HETE, hydroxyeicosatetraenoic acid; AA, arachidonic acid.
Figure 5 Effect of L-NAME on iso PGE2 and iso PGF2 production of rat cerebral arteries. Arteries
were incubated with AA and indomethacin in the absence and presence of L-NAME. Metabolites were
extracted and analyzed by liquid chromatography–mass spectrometry. Selected ion chromatogram m/z
351 (iso PGE2) (A) and m/z 353 (iso PGF2) (B). Migration times of known standards are shown on each
chromatogram. * indicates a marked change in production following treatment with L-NAME.
Fig. 5A), whereas 8-iso-PGF2 production increased 3-fold with L-NAME treatment
(179 and 583 ng/ml, respectively; Fig. 5B). In addition, several unidentified PGF2-type
isoprostanes were produced by cerebral arteries and were increased by L-NAME (Fig. 5B).
Effect of 8-isoprostane F2 on EDH
Since cerebral arteries synthesize isoprostanes, and L-NAME increased their production,
we investigated the effects of 8-iso-PGF2 on vascular tone and EDH. 8-iso-PGF2 caused
concentration-dependent contraction of cerebral arteries that was fully inhibited by the TP
receptor antagonist SQ 29,548 (10 µM, Fig. 6A).
In control vessels, exogenous application of 8-iso-PGF2 (1 µM) caused significant
depolarization and constriction (Em− 49.9± 2.5 vs−40.7± 2.5 mV and tension 1.0± 0.2
vs 3.9± 0.3 mN pre- and post-8-iso-PGF2, respectively, n = 9,P < 0.05) but did not
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Figure 6 Effect of isoprostane F2α (8-iso PGF) on middle cerebral arteries. (A) Concentration-response curve showing constriction produced by
8-iso PGF in rat middle cerebral arteries that were able to synthesize NO. This constriction was completely blocked by the selective TP antagonist SQ
29,543. (B) Original traces showing the effect of pre-incubation of 8-iso PGF2 on EDH evoked by SLIGRL (20 µM) in rat middle cerebral arteries
that were able to synthesize NO. 8-iso PGF2 did not significantly affect control EDH (upper panel) but subsequent inhibition of KCa2.3 (TRAM-34;
1 µM) virtually abolished EDH (lower panel). The vessel viability was assessed by addition of 15 mM K+ which evokes endothelium-independent
hyperpolarization and relaxation. (C) Bar graph showing the effect of 8-iso PGF on EDH. Control EDH is unaffected by 8-iso PGF, TRAM-34 alone
significantly inhibited EDH and apamin is without effect. The combination of apamin and TRAM-34 had no further effect to TRAM-34 alone.
The data shows that 8-iso PGF2 inhibits the KCa2.3 component of EDH normally seen under these conditions.
∗P < 0.05 indicates a significant
difference from control. ΨP < 0.05 indicates a significant difference from 8-iso-PGF2α.
significantly affect SLIGRL-induced EDH (−28.0 ± 2.7 vs 23.7 ± 2.3 mV, pre- and
post-8-iso-PGF2 respectively, n= 9; Figs. 6B and 6C). In the presence of 8-iso-PGF2, EDH
was significantly inhibited by TRAM-34 alone (−13.6± 2.8 mV, P < 0.05,n = 5; Figs. 6B
and 6C) whereas apamin alone had no effect (−25.5± 5.9 mV, n = 4; Fig. 6C); nor did it
have any additional affect in combination with TRAM-34 (−9.6± 1.1 mV, n= 9; Fig. 6C).
The residual hyperpolarization was blocked by addition of iberiotoxin (−3.2± 0.8 mV,
n= 7; Fig. 6C).
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DISCUSSION
This study is the first to demonstrate that a LOX metabolite(s) of AA, contributes to
endothelium-dependent hyperpolarization (EDH) in the rat middle cerebral artery and
thus may be the, as yet, unidentified AA metabolite involved in EDH responses in the
middle cerebral artery. Following inhibition of NOS with L-NAME, the profile of AA
metabolism is altered. There is no change in production of LOX products; however,
L-NAME increased 8-iso-PGF2 production and the production of other iso-PGF2 isomers.
We suggest that the increase in isoprostane formation causes the TP receptor-dependent
loss of KCa2.3-mediated component of EDH, a phenomenon we had previously attributed
to TxA2 (McNeish & Garland, 2007).
The findings that 15-LOX metabolites, namely HEETA and THETA, contribute to
the EDH response in rabbit arteries lead us to investigate whether these metabolites
contributed to EDH in the rat middle cerebral artery. This was of particular interest
as EDH responses in this artery have a component dependent upon an unidentified
AA metabolite (McNeish & Garland, 2007; You, Golding & Bryan, 2005). Analysis of AA
metabolism by the middle cerebral artery indicates LOX products are generated whereas
epoxygenase metabolites such as EETs are not. In control arteries, EDH induced by
SLIGRL-NH2 is significantly attenuated by three structurally distinct inhibitors of LOX
enzymes. These findings clearly indicate that EDH in this artery is mediated, at least in
part, by LOX metabolites.
KCa channels mediate the EDH responses to LOX metabolites; the most likely candidates
are either 12-HETE, a 12-LOX metabolite, (Zink et al., 2001) or HEETA and THETA,
15-LOX metabolites (Campbell et al., 2003; Chawengsub et al., 2008; Chawengsub, Gauthier
& Campbell, 2009). These metabolites are all produced by the rat middle cerebral artery
consistent with the expression of a 12/15-LOX. Interestingly, 12-HETE (30 nM) had no
effect on membrane potential or tone in cerebral arteries (data not shown). Therefore, the
15-LOX products, HEETA or THETA, are most likely the AA metabolites that contribute to
EDH responses in this artery.
HEETA and THETA stimulate hyperpolarization of rabbit arteries by direct stimulation
of KCa2.3 (Campbell et al., 2003; Chawengsub et al., 2008). As HEETA is rapidly
metabolized by sEH to THETA, it is difficult to distinguish between the activities of these
two eicosanoids. In order to ascertain which of these metabolites contributes to EDH, we
used a selective sEH inhibitor tAUCB (Liu et al., 2009); tAUCB does not affect total EDH
but selectively augments the KCa2.3 component of EDH. As inhibition of sEH prevents
the rapid breakdown of HEETA to THETA, it is likely that the HEETA, not THETA, is the
15-LOX product involved in EDH. In rabbit arteries, both these LOX products directly
stimulate KCa2.3 located on the SMC layer and thus act as diffusible EDHFs. However, such
an action is unlikely in the rat middle cerebral artery as KCa2.3 are expressed solely on the
endothelium (Cipolla et al., 2009; McNeish et al., 2006). Thus, it is more likely that HEETA
contribute to EDH by acting as an intracellular or autocrine modulators of endothelial
KCa2.3, as proposed for other AA metabolites involved in EDH responses such as EETs
(Campbell & Falck, 2007; Edwards, Feletou & Weston, 2010). More recently, metabolites
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of AA have also been shown to have effects on transient receptor potential channels
evoking subsequent KCa channel activation and dilation (Earley, 2011; Sonkusare et al.,
2012; Zheng et al., 2013).
Under the experimental conditions described above, the middle cerebral artery pro-
duces NO and the KCa2.3 channel contributes to EDH. However, under conditions where
NOS is blocked to observe the EDH response in isolation, the KCa2.3 channel component
of hyperpolarization is lost and only KCa3.1 channels contribute to the EDH response
(Marrelli, Eckmann & Hunte, 2003; McNeish, Dora & Garland, 2005; McNeish et al., 2006).
The loss of the KCa2.3 channel component involves stimulation of TP receptors (McNeish
& Garland, 2007). Since LOX products appear to selectively augment KCa2.3 channels, we
postulated that TP-mediated inhibition of this channel may be due to a reduction in LOX
metabolites. However, following NOS inhibition, there was actually an increase in the AA
metabolites corresponding to HEETA, THETA and HETEs. Inhibition of sEH (a treatment
that would be expected to protect HEETA production and thus KCa2.3 channel activation)
failed to restore KCa2.3 channel function when NOS was inhibited. Therefore, loss of
KCa2.3 function following NOS inhibition does not involve decreased production of LOX
metabolites. This finding supports a previous study that demonstrated inhibition of LOX
has no effect on EDH responses following inhibition of NOS (You, Golding & Bryan, 2005).
A potential explanation for the loss of KCa2.3 channel function following NOS
inhibition, despite increased production of LOX metabolites, is that TP mediated signaling
mechanisms overcome the actions of LOX metabolites. TP receptor stimulation inhibits
KCa2.3-mediated responses in control arteries able to synthesize NO (McNeish & Garland,
2007) by a Rho kinase dependent mechanism (McNeish et al., 2012). Therefore, we wished
to confirm that synthesis of the endogenous activator of TP receptors, TxA2, is increased
following NOS synthase inhibition, as previously suggested (McNeish & Garland, 2007).
Surprisingly, we did not detect TxA2 production with, or without, NOS inhibition.
However, following NOS inhibition there was an increase in production of isoprostanes
which also stimulate TP receptors (Crankshaw, 1995; Elmhurst, Betti & Rangachari, 1997).
The most likely source of isoprostanes is the non-enzymatic reaction of either free or
esterified AA with reactive oxygen species such as superoxide (Morrow et al., 1990). Due
to our sampling technique of measuring isoprostanes in the incubation medium it is
likely that we were measuring isoprostanes produced from free AA (although we cannot
eliminate the possibility that esterified isoprostanes were also released into the medium);
however the endothelium is the mostly likely source of the isoprostanes as it is the major
source of AA metabolites in vascular tissues (Rosolowsky & Campbell, 1993; Rosolowsky &
Campbell, 1996). Interestingly, superoxide production is high in the cerebral vasculature
when compared to systemic vessels due to increased expression of NADPH oxidase (Miller
et al., 2005). As NO reacts rapidly with superoxide, it is conceivable NOS inhibition in
the middle cerebral artery increases free superoxide produced from NADPH oxidase and
therefore isoprostane synthesis leading to stimulation of TP receptors and loss of KCa2.3
function. The superoxide scavenger tempol prevented loss of KCa2.3 function following
inhibition of NOS supporting this hypothesis. Furthermore, using LC/MS, we detected
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Figure 7 Schematic showing the role of LOX products on EDH responses in the middle cerebral
artery, the proposed effect that inhibition of NOS and increase in isoprostane production has on the
EDH response. (1) Under conditions where middle cerebral arteries can synthesize NO, metabolism
of AA by LOX produces HEETA which is metabolized by sEH to THETA. Both can activate KCa2.3
channels. As tAUCB augments the KCa2.3 response HEETA is likely to be the metabolite involved. (2)
Under these conditions the EDH response also involves activation of KCa3.1 and KCa1.1 channels to
produce smooth muscle cell hyperpolarization and relaxation. (3) When NO is synthesized (4) it rapidly
reacts with superoxide preventing production of isoprostanes, when NOS is inhibited (5) this inhibitory
effect of NO on isoprostane production is reduced. Endothelial cells are the major source of vascular AA
metabolites but it is possible NO prevents isoprostane production in SMCs. The subsequent stimulation
of the TP receptor (6) inhibits the KCa2.3 component of EDH as we have previously reported (McNeish
& Garland, 2007; McNeish et al., 2012). Solid lines/arrows represent known pathways, dashed lines
indicate possible/unconfirmed pathways, green arrows are stimulatory pathways, red lines/text represent
inhibitory pathways/blocking agents. EC, endothelial cell; SMC, smooth muscle cell.
increased production of 8-iso-PGF2 and several as yet unidentified PGF2-type isoprostanes
following NOS inhibition. While the source of superoxide was not investigated in this
study a similar increase in isoprostane production following inhibition of NOS has been
observed kidneys where it was reversed by tempol and knock out of gp91 phox (Haque &
Majid, 2008; Kopkan & Majid, 2006), we thus speculate that a similar NADPH dependent
mechanism is responsible for increased isoprostane production in cerebral arteries. In
arteries not treated with a NOS inhibitor, exogenous 8-iso-PGF2 constricted the middle
cerebral artery via a TP receptor dependent mechanism and mimicked the ability of other
TP receptor agonists (McNeish & Garland, 2007) to inhibit the KCa2.3 component of EDH.
Thus, increased production of 8-iso-PGF2 following NOS inhibition is likely to cause the
loss of the KCa2.3 component of EDH.
The data are summarized in Fig. 7, they indicate the novel finding that LOX metabolites
of AA, most likely HEETA, contribute to EDH in the middle cerebral artery and that
inhibition of sEH with the selective inhibitor tAUCB increases the KCa2.3 component of
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hyperpolarization. However, the loss of KCa2.3 function following inhibition of NOS is
not restored by tAUCB treatment. Instead, NOS inhibition increases F-type isoprostane
production resulting in TP receptor stimulation (Fig. 7), the loss of KCa2.3 responses and
elimination of the effect of HEETA. These findings may have important implications in
diseases associated with loss of NO signaling such as stroke and coronary artery disease
where increased isoprostane production has been detected (Patrono & FitzGerald, 1997).
This pathway may be related to the severity of the disease (Wang et al., 2006). Our data
indicate that inhibition of sEH may not be an effective treatment for cerebrovascular
disease but prevention of isoprostane formation may be beneficial.
Abbreviations
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